Press Releases

PASADENA, Calif. --(BUSINESS WIRE)--May 2, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 29, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024 Type: Fireside Chat Presentation

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 26, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024 , at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024 .

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy

- Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated PASADENA, Calif. --(BUSINESS WIRE)--Apr. 7, 2024-- Arrowhead Pharmaceuticals, Inc.

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 1, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 30, 2024 , the Company’s Board of Directors approved “inducement” grants to 32 new employees under Rule

- Expanded Access Program initiated to make investigational plozasiran available to patients with familial chylomicronemia syndrome - New SHASTA-2 Phase 2 clinical data in patients with severe hypertriglyceridemia to be presented at ACC.24 PASADENA, Calif. --(BUSINESS WIRE)--Mar.

- Preclinical data show ARO-DM1 reduces muscular DMPK expression and corrects spliceopathies, which could lead to improved muscle strength and function PASADENA, Calif. --(BUSINESS WIRE)--Mar. 8, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first

PASADENA, Calif. --(BUSINESS WIRE)--Mar. 4, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference – March 6, 2024 Type: Fireside Chat Presentation Date: March 6, 2024